Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management
EP. 1: Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.
EP. 2: Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.
EP. 3: Pharmacy-Driven Challenges
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.
EP. 4: Real-World Insights and PROMPT-LIPID
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.
EP. 5: Social Determinants of Health
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.
EP. 6: The 2013 Guideline Shift
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how removing LDL-C targets in 2013 shifted focus from outcomes to statin use, weakening control efforts.
EP. 7: Unintended Consequences of Metric Changes
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.
EP. 8: Reinstating LDL-C Targets
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.
EP. 9: International LDL Thresholds
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how global LDL thresholds below 55 mg/dL influence care and challenge U.S. practice to evolve.
EP. 10: Nonstatin Therapy Decisions
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how nonstatin agents are chosen and when combination therapy should be introduced for high-risk patients.
EP. 11: PCSK9 Inhibitor Underuse
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
EP. 12: Payer and Prior Authorization Barriers
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
EP. 13: Adherence and Persistence
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.
EP. 14: Cumulative LDL-C Exposure
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.
EP. 15: Economic Burden and Systemwide Strategies
ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.
